Migraine Drugs Market to Reach USD 13.6 Billion by 2035

According to analysts at Vantage Market Research, the Global Migraine Drugs Market size is worth USD 6.37 Billion in 2024 and is projected to reach USD 21.59 Billion by 2035, growing at a CAGR (Compound Annual Growth Rate) of 11.75% from 2024 to 2035. Key trends of market include rise of CGRP inhibitors, personalized treatments, non-invasive therapies, advancements in drug delivery methods, growing patient awareness, and increasing demand for effective, targeted migraine treatments.

Market Overview

The rising prevalence of migraines worldwide serves as a significant factor drives the growth of the migraine drugs market. Improvements in drug development are significantly advancing the migraine drugs market industry. The introduction of novel drug categories like CGRP inhibitors and gepants has revolutionized treatment by offering targeted mechanisms that effectively reduce the severity and frequency of migraines. These innovations are driving continued progress and market growth.  

The rising government regulations for migraine drugs, increased adoption of innovative drugs classes, and increasing FDA approvals are the major factors driving the market growth over the forecast period. For instance, in September 2021, AbbVie announced that the U.S. Food and Drug Administration (FDA) approved QULIPTA™ (atogepant) for the preventive treatment of episodic migraine in adults. QULIPTA is the first and only oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) specifically developed for the preventive treatment of migraine.

Organon & Lilly Enter Commercialization Agreement in Europe for Two Migraine Medicines

• In December 2023, Organon, a global healthcare company with a focus on women’s health, announced an agreement with Eli Lilly and Company (Lilly) to become the sole distributor and promoter for the migraine medicines Emgality® (galcanezumab) and RAYVOW™(lasmiditan) in Europe

Key Takeaways from the Report

• North America dominated the market with largest market share of 41.30% in 2024. Market is driven by a high prevalence of migraine cases, advanced healthcare infrastructure
• In 2024, based on the Treatment, the Acute category accounted largest  market share of 62.70%. Acute treatment involves a range of medications and approaches aimed at relieving symptoms during a migraine episode
• Based on the Therapeutic class, the CGRP monoclonal antibodies category accounted for significant market share of 58.50% in 2024.
• In 2024, based on the Route of Administration, the Injectable category accounted largest share market. 
• In 2024, based on the Age group, the Adult category accounted largest share of 53.80% in market.
• Based on the Availability, the Prescription Drugs category accounted for significant market share of 79.40% in 2024. Prescription drugs are widely used treatment option for managing migraines. The segment is driven by rising prevalence of migraines

Top Companies

• AbbVie Inc
• Amgen Inc
• Teva Pharmaceuticals Industries
• GSK Plc
• Eli Lily and Company
• Pfizer Inc
• Bausch Health Companies Inc
• Gensco Pharma
• Impel Pharmaceuticals Inc
• Tonix Medicines Inc
• Currax Pharmaceuticals LLC

Report Coverage

Our market research reports provide comprehensive insights that are essential for strategic decision-making. We cover all key aspects of the market, including dynamics such as drivers, restraints, opportunities, and challenges, alongside the latest industry trends. Our analysis includes an in-depth technology roadmap, product life cycle evaluation, and PESTLE analysis, ensuring a thorough understanding of the market environment. We also assess GDP growth outlooks, examine regional market landscapes, and evaluate the impact of major events like the COVID-19 pandemic. Additionally, our reports feature a detailed competitive landscape, including company market shares and profiles, providing actionable intelligence to empower your business strategies.

Latest News

Amazon Pharmacy now provides home delivery of select diabetes, obesity, and migraine medications to LillyDirect patients

• In March 2024, Lilly has selected Amazon Pharmacy as a dispensing pharmacy option, allowing patients to receive fast, free delivery of medications and 24/7 access to clinical pharmacists